Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026962 · ClinicalTrials.gov registry record · Phase 2
Effects of Raloxifene on Hormone Levels
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00026962: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00026962 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026962, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Blood levels of the hormones estradiol and progesterone are of interest in evaluating ovarian function. However, because these hormone levels vary from day to day, blood samples must be taken very often or elaborately timed to specific phases of the menstrual cycle. A method has now been developed for measuring estradiol and progesterone levels in saliva. This study will test the accuracy of this method and examine whether salivary levels of these hormones change after treatment with raloxifene. Hormone levels will be measured during 3 menstrual cycles in women currently enrolled in the clinical study, "A Phase II Trial of Two Doses of Raloxifene in Women at Risk of Developing Invasive Breast Cancer." Participants will provide a saliva sample every morning for about a month during three collection periods-1 month before beginning raloxifene treatment, and 3 and 12 months after treatment starts. Patients will be given kits for collecting the samples and mailing them to the laboratory at the end of each collection period.
Interventions
- PROCEDURE measuring estradiol and progesterone levels in saliva
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1999-09 |
| Est. Completion | 2003-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026962
The ClinicalTrials.gov registry entry for NCT00026962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which measuring estradiol and progesterone levels in saliva is the first listed.
NCT00026962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026962 about?
NCT00026962 is a clinical study titled "Effects of Raloxifene on Hormone Levels". Blood levels of the hormones estradiol and progesterone are of interest in evaluating ovarian function. However, because these hormone levels vary from day to day, blood samples must be taken very often or elaborately timed to specific phases of the menstrual cycle. A method has now been developed f...
What is the current status of trial NCT00026962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 1999-09. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00026962?
The interventions under investigation include: measuring estradiol and progesterone levels in saliva (PROCEDURE).
Who is sponsoring clinical trial NCT00026962?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.